Volume 8: Issue 1

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Vallerie V. McLaughlin, MD, Chair, SLC, University of Michigan Health System, Ann Arbor, Michigan
David B. Badesch, MD, SLC Immediate Past-Chair, University of Colorado Health Sciences Center, Aurora, Colorado
John H. Newman, MD, SLC Vice-Chair, Vanderbilt Medical School, Nashville, Tennessee
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, Pennsylvania
Todd Bull, MD, University of Colorado Health Sciences Center, Denver, Colorado
Richard Channick, MD, Editor-in Chief, Advances in Pulmonary Hypertension

A roundtable discussion on ethical issues relating to the conduct of randomized clinical trials (RCTs) with pulmonary arterial hypertension (PAH) patients was held during the May 2009 American Thoracic Society meeting in San Diego. Scott Halpern, MD, PhD, MBE, Assistant Professor of Medicine and Epidemiology, Pulmonary, Allergy, and Critical Care Division, and Senior Fellow in the Center for Bioethics at the University of Pennsylvania, Philadelphia, facilitated the discussion among participants Myung H. Park, MD, Director, Pulmonary Vascular Diseases Program, University of Maryland School of Medicine, Baltimore, Maryland; David B. Badesch, MD, Professor of Medicine, Divisions of Pulmonary Sciences and Critical Care Medicine, and Cardiology, and Clinical Director of the Pulmonary Hypertension Center, University of Colorado at Denver Health Sciences Center; and Michael D. McGoon, MD, Professor of Medicine, Department of Cardiology, Pulmonary Hypertension Clinic, Mayo Clinic, Rochester, Minnesota.

A New Day for PAH

Editor's Memo

The Scientific Leadership Council of the Pulmonary Hypertension Association

Near-Term Novel Therapies for PAH

Introduction—“The Need”

Evaluating Recent Therapeutic Trials in Pulmonary Arterial Hypertension: Raising the Bar for Clinical Investigation

Update on the Development of Oral Prostacyclin Analogs for the Treatment of PAH

Ethical Considerations for RCTs in PAH

A Meeting of Minds From Around the World

Conference Abstracts

Guest Editor’s Memo

A Roundtable Discussion Addressing Patient-Centered Care and Quality of Life in Patients With Pulmonary Arterial Hypertension

Editor’s Memo

Pulmonary Hypertension Associated With Parenchymal Lung Disease